Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, J J, Feng, L, Thomas, S K, Berkova, Z, Weber, D M, Wang, M, Qazilbash, M H, Champlin, R E, Mendoza, T R, Cleeland, C, Orlowski, R Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771967/
https://www.ncbi.nlm.nih.gov/pubmed/26871714
http://dx.doi.org/10.1038/bcj.2016.4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771967/
https://www.ncbi.nlm.nih.gov/pubmed/26871714
http://dx.doi.org/10.1038/bcj.2016.4

Ejemplares similares